UPC vs. PMN, RNXT, BOLT, IPA, VIRX, APRE, SPRB, JAN, BIVI, and ONCT
Should you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include ProMIS Neurosciences (PMN), RenovoRx (RNXT), Bolt Biotherapeutics (BOLT), ImmunoPrecise Antibodies (IPA), Viracta Therapeutics (VIRX), Aprea Therapeutics (APRE), Spruce Biosciences (SPRB), JanOne (JAN), BioVie (BIVI), and Oncternal Therapeutics (ONCT). These companies are all part of the "pharmaceutical preparations" industry.
ProMIS Neurosciences (NASDAQ:PMN) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
In the previous week, ProMIS Neurosciences had 2 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 2 mentions for ProMIS Neurosciences and 0 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 1.25 beat ProMIS Neurosciences' score of 0.00 indicating that ProMIS Neurosciences is being referred to more favorably in the media.
ProMIS Neurosciences presently has a consensus price target of $8.00, suggesting a potential upside of 403.14%. Given Universe Pharmaceuticals' higher probable upside, equities analysts clearly believe ProMIS Neurosciences is more favorable than Universe Pharmaceuticals.
ProMIS Neurosciences' return on equity of 0.00% beat Universe Pharmaceuticals' return on equity.
ProMIS Neurosciences received 2 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users.
50.1% of ProMIS Neurosciences shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 6.4% of ProMIS Neurosciences shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
ProMIS Neurosciences has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.
Universe Pharmaceuticals has higher revenue and earnings than ProMIS Neurosciences.
Summary
ProMIS Neurosciences beats Universe Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Universe Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Universe Pharmaceuticals Competitors List
Related Companies and Tools
